Black Diamond Therapeutics, Inc. — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications5liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
silevertinib in combination with temozolomideThe purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following questions: * How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM? * What are the side effects participants have when taking the study drug (silevertinib combined with temozolomide)? * Can the study drug (silevertinib combined with temozolomide) help participants with GBM live longer without disease progression compared to treatment with temozolomide alone?	Cancer	Phase 2	Ralentissement de la progression	United States	À vérifier
temozolomide (TMZ)The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following questions: * How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM? * What are the side effects participants have when taking the study drug (silevertinib combined with temozolomide)? * Can the study drug (silevertinib combined with temozolomide) help participants with GBM live longer without disease progression compared to treatment with temozolomide alone?	Cancer	Phase 2	Ralentissement de la progression	United States	À vérifier
silevertinib in combination with temozolomideThe purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following questions: * How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM? * What are the side effects participants have when taking the study drug (silevertinib combined with temozolomide)? * Can the study drug (silevertinib combined with temozolomide) help participants with GBM live longer without disease progression compared to treatment with temozolomide alone?	Cancer	Phase 2	Ralentissement de la progression	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
silevertinib in combination with temozolomide	Cancer	Phase 2	NCT07326566	Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII	RECRUITING

Publications

5

Molécule	Indication / population	Titre	Journal	Date
temozolomide (TMZ)		Rewiring cell death and evading repair: Evolution of temozolomide and emerging strategies against resistant glioblastoma.	European journal of medicinal chemistry
temozolomide (TMZ)		A dual-channel electron expressway triggers piezocatalytic ferroptosis-mitochondrial catastrophe cascade for anti-glioblastoma therapy.	Biomaterials
silevertinib in combination with temozolomide		Selective inhibition of ELFN2-containing PP1 hinders autophagy and enhances temozolomide sensitivity in glioblastoma.	Cancer letters
silevertinib in combination with temozolomide		Integrative transcriptomics, machine learning, and molecular docking derive a DAM-like macrophage signature for risk stratification and therapeutic nomination in glioblastoma.	Computational biology and chemistry
silevertinib in combination with temozolomide		Trichodermin exhibits potent anti-glioblastoma activity by inducing cell cycle arrest and apoptosis, suppressing invasion, and enhancing temozolomide efficacy.	Journal of enzyme inhibition and medicinal chemistry